Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

BACKGROUND: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE: Our aim was to assess the response to ixekizumab in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E. M., Puig, Luis, Weisman, Jamie, Dutronc, Yves, Kerr, Lisa Farmer, Ilo, Dapo, Mallbris, Lotus, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884910/
https://www.ncbi.nlm.nih.gov/pubmed/28074446
http://dx.doi.org/10.1007/s40257-016-0246-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884910/
https://www.ncbi.nlm.nih.gov/pubmed/28074446
http://dx.doi.org/10.1007/s40257-016-0246-9

Ejemplares similares